Screen Shot 2021-12-01 at 9.56.39 AM.png

Franklin King, MD

The Promise Of Psychedelics: A Critical Look At The Therapeutic Potential Of Psychedelic-Assisted Treatments

July 24th - July 28th, 2023

This course is also available Live-Online!

JOIN THE IN-PERSON WAITLIST HERE!

This course is no longer available.

Quantity

IN-PERSON COURSE SOLD OUT!

Price:

$0.00

VIEW CART

ADD TO CART

Error text

15 Hour In-Person & Live-Online Course

Monday - Friday: 9:00a.m. - 12:30p.m. EDT / 30-Minute Break Daily

Check your local time

Sold out

Course Description

The meteoric rise in interest in psychedelics over the last several years has led to an avalanche of media attention, academic publications, and capital investment. Within this current era of psychedelic research, there are numerous distortions related to both positive and negative biases for and against psychedelics by various groups.

Used by Indigenous cultures for thousands of years for diverse medicinal and ritual purposes, psychedelics were also briefly an area of intense research interest in midcentury western medicine before falling victim to a moral panic and the political machinations of America’s so-called War on Drugs. Over the last twenty years, renewed research has shown potential for psychedelics to treat symptoms of numerous psychiatric disorders, as well as to shed new light on consciousness, philosophy of mind, and spirituality. Challenges to realizing these potentials are myriad and include issues of cost, justice, a limited understanding of potential harms, questions on role and form of therapy, and a dominant paradigm in medical culture of biomedical reductionism.

The purpose of this course is to review the history, pharmacology, clinical studies, and potential future applications of psychedelics and psychedelic-assisted psychotherapy, with an orientation toward critical thinking in understanding why some of the current biases and issues within psychedelic research and the public narrative exist, and the challenges that psychedelics will likely face as they become “mainstreamed”. The format will consist of didactic sessions and small group discussions. Specific readings will be assigned and participants will be asked to share and reflect. Following this course, participants should have a comprehensive understanding of psychedelics and psychedelic medicine.

Monday

Introduction and History of Psychedelics
Review history of indigenous use: prehistoric into modern times
Cultural history in the USA
‘First wave of psychedelic research’
Neurobiology and Mechanisms of Action
Pharmacology, different classes of psychedelics
Imaging and other neuroscience research, psychological mechanisms

Tuesday

Clinical Trials in Psychedelics I
Key studies in psychedelics (PTSD, MDD)
Barriers to conducting research and trial design issues
Clinical Trials II and Harm Reduction
Addictions, Microdosing
Medication Interactions, Contraindications, Harm Reduction

Wednesday

Psychedelic-Assisted Therapy
History of therapies used in past
Contemporary models
Potential future hybridizations

Thursday

Psychedelics and Meditation, other Non-ordinary States
Overlaps in mechanisms
Psychedelics as a practice?
Somatic/Psychosomatic Disorders
Functional medical conditions
Psychedelics and immune modulation

Friday

Psychedelics, Serious Illness, and Death and Dying
Socio-psychedelic Imaginaries: Psychedelics, Reification, and Capitalism
Systemic economic and justice issues in psychedelic research
Psychedelic Epistemology and Critical Psychiatry
Final Reflections and Wrap-Up

Franklin King, MD is a psychiatrist at the Massachusetts General Hospital and an Instructor in Psychiatry at Harvard Medical School. He is a graduate of the University of Massachusetts Medical School, after which he completed residency in adult psychiatry at the MGH/McLean program. He has completed post-residency fellowships, both at MGH, in Consult Liaison Psychiatry and a research fellowship at the Cardiac Psychiatry Research Center. Dr. King has practiced in a variety of clinical roles at MGH including the Neuropsychiatry Clinic, the Adult Outpatient Clinic, the Center for Anxiety and Traumatic Stress Disorders Clinical and Research Program, the Avery Weissman Psychiatric Consult Service, and the Acute Psychiatry Service. He has long held an interest in bringing the benefits of psychedelic-assisted therapies to the vast array of patients who are currently left inadequately treated by existing and available psychiatric interventions, and is currently the Director of Training and Education at the Center for Neuroscience of Psychedelics, in which role he is actively involved in educational projects to clinician groups and residents on psychedelics and psychedelic-assisted therapies. Dr. King is also a Principle Investigator and Co-Investigator on studies involving psilocybin-assisted therapy and MDMA-assisted therapy, respectively, at MGH.

Speaker Disclosures:

Financial: Franklin King owns stock in Compass and Cybin. He has received consulting fees from Cybin, speaker fees from Vital, and receives stock equity as a scientific advisory board member for Apex Pharmaceuticals. He receives a speaking honorarium from MAK Continuing Education, LLC, Cape Cod Institute.

Non-financial: Franklin King has no relevant non-financial relationships with ineligible organizations.

Upon completion of this course participants will be able to:

1. Summarize the history of indigenous use of psychedelics from prehistoric into modern times

2. Identify the different pharmacology classes of psychedelics

3. Discuss current imaging and neurological research studies on psychedelics

4. Discuss current phase I and phase II psychedelic clinical trials and findings

5. Discuss the use of psychedelics in the treatment of addiction

6. Discuss the history of psychedelic-assisted therapy models, contemporary models, and areas for further research regarding clinical application

7. Discuss the difference and overlaps in the mechanisms of psychedelics, meditation, and other non-ordinary states

8. Discuss the use of psychedelics with serious illness and end of life care

9. Discuss issues of diversity, equity and access in psychedelic research and medicine

Creative Arts Therapists:

New York: MAK Continuing Education, LLC, Cape Cod Institute is recognized by the New York State Education Department's State Board for Mental Health Practitioners as an approved provider of continuing education for licensed creative arts therapists. # CAT-0090.

Educators:

For eligibility information contact your State certifying authority.

Massachusetts: Educators in Massachusetts are eligible for 15 Professional Development Points (PDPs) for each program attended. MAK Continuing Education, LLC is a registered Professional Development Provider (PD number: U20190001) with the Massachusetts Department of Elementary and Secondary Education (DESE).

Marriage and Family Therapists:

Massachusetts: This activity has been certified by NEAFAST on behalf of the Massachusetts Board of Registration of Allied Mental Health & Human Services Professions, for LMFT professional continuing education. Certification # PC- 041851.

Physicians & Nursing Professionals:

A.C.C.M.E. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Milton H. Erickson Foundation, Inc., and MAK Continuing Education, LLC, Cape Cod Institute. The Milton H. Erickson Foundation, Inc., is accredited by the ACCME to provide continuing medical education for physicians.

A.M.A. The Milton H. Erickson Foundation, Inc., designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professional Counselors:

MAK Continuing Education, LLC, Cape Cod Institute has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7187. Programs that do not qualify for NBCC credit are clearly identified. MAK Continuing Education, LLC, Cape Cod Institute is solely responsible for all aspects of the programs.

Psychoanalysts:

Psychologists: MAK Continuing Education, LLC is approved by the American Psychological Association to sponsor continuing education for psychologists. MAK Continuing Education, LLC maintains responsibility for this program and its content.

California: MAK Continuing Education, LLC, Cape Cod Institute is approved by the CPA OPD to sponsor continuing professional education for psychologists. MAK Continuing Education, LLC, Cape Cod Institute maintains responsibility for this program and its content. CPA OPD Provider Code: MAK001.

Canada: MAK Continuing Education, LLC, Cape Cod Institute is approved by the Canadian Psychological Association to offer continuing education for psychologists. MAK Continuing Education, LLC, Cape Cod Institute maintains responsibility for the program.

Connecticut: CE credit is available. This course consists of 15 continuing education credit hours for Connecticut Psychologists. CT Gen Stat Sec. 20-191c Continuing Education (b)(3) confirms acceptance of continuing education programs relevant to psychology from a nationally recognized provider of continuing education seminars. MAK Continuing Education, LLC, Cape Cod Institute is a nationally recognized provider of continuing education seminars with multiple national CE approvals.

New York: MAK Continuing Education, LLC, Cape Cod Institute is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists # PSY-0102.

Ohio: MAK Continuing Education, LLC, Cape Cod Institute is a OPA-MCE Approved Provider. Approved Provider: #854261519.

Pennsylvania: MAK Continuing Education, LLC, Cape Cod Institute is approved by the Pennsylvania State Board of Psychology to offer continuing education for psychologists. Provider # PSY000226. MAK Continuing Education, LLC, Cape Cod Institute maintains responsibility for the program. This program qualifies for 15 continuing education hours.

Social Workers:

ASWB ACE: MAK Continuing Education, LLC, Cape Cod Institute, Provider #1197, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. MAK Continuing Education, LLC, Cape Cod Institute, maintains responsibility for this course. ACE provider approval period: 8/20/2022- 8/20/2025. Social workers completing this course receive 15 continuing education credits.

ASWB ACE Individual Course Applications (NJ Social Workers): The Promise of Psychedelics: A Critical Look at the Therapeutic Potential of Psychedelic- Assisted Treatments, Course #4931, is approved by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program to be offered by MAK Continuing Education, LLC, Cape Cod Institute as an individual course. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE course approval period: 5/2/2023 - 5/2/2025. Social workers completing this course receive 15 General continuing education credits.

New York: MAK Continuing Education, LLC, Cape Cod Institute is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers # SW-0649.

For all other CE approval statements, please visit our CE page and search by your discipline.

Course Content Level: beginner, intermediate, and advanced. This course is open, and content is suitable for all clinicians and learning levels, beginning, intermediate and advanced.

Downloadable Course Brochure

Hear more from

Franklin King, MD

00:00 / 01:04

What Alumni are Saying...

Learn more about the Cape Cod Institute from former participants

Questions?

0

Franklin King, MD